Arcturus Therapeutics Holdings Inc
$ 7.29
-4.20%
16 Jan - close price
- Market Cap 207,140,000 USD
- Current Price $ 7.29
- High / Low $ 7.74 / 7.29
- Stock P/E N/A
- Book Value 8.24
- EPS -2.46
- Next Earning Report 2026-03-05
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA -0.15 %
- ROE -0.27 %
- 52 Week High 24.17
- 52 Week Low 5.85
About
Arcturus Therapeutics Holdings Inc. is an innovative biopharmaceutical company headquartered in San Diego, California, specializing in RNA-based therapeutics designed to tackle significant unmet medical needs, including liver and respiratory conditions. Utilizing its proprietary RNA delivery technology, the company is advancing a robust pipeline of drug candidates with the potential to improve patient outcomes substantially. With a commitment to technological excellence and a deep understanding of the biopharmaceutical landscape, Arcturus is well-positioned to seize growth opportunities within the rapidly evolving biotechnology sector, driving forward the future of healthcare solutions.
Analyst Target Price
$35.25
Quarterly Earnings
| Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | Mar 2023 | Dec 2022 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2025-11-10 | 2025-08-04 | 2025-06-13 | 2025-03-05 | 2024-11-07 | 2024-08-05 | 2024-05-08 | 2024-03-07 | 2023-11-14 | 2023-08-07 | 2023-05-09 | 2023-03-28 |
| Reported EPS | -0.49 | -0.34 | -0.52 | -1.11 | -0.26 | -0.64 | -1 | -0.32 | -0.61 | -1.98 | 1.87 | 4.43 |
| Estimated EPS | 5.53 | 3.21 | -1.19 | -0.4943 | -1.22 | -1.6 | -1.19 | -0.99 | -1.69 | -0.21 | 0.06 | 0.98 |
| Surprise | -6.02 | -3.55 | 0.67 | -0.6157 | 0.96 | 0.96 | 0.19 | 0.67 | 1.08 | -1.77 | 1.81 | 3.45 |
| Surprise Percentage | -108.8608% | -110.5919% | 56.3025% | -124.56% | 78.6885% | 60% | 15.9664% | 67.6768% | 63.9053% | -842.8571% | 3016.6667% | 352.0408% |
Next Quarterly Earnings
| Dec 2025 | |
|---|---|
| Reported Date | 2026-03-05 |
| Fiscal Date Ending | 2025-12-31 |
| Estimated EPS | -0.87 |
| Currency | USD |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: ARCT
2026-01-17 11:00:00
This article provides a price-driven insight for Arcturus Therapeutics Holdings Inc. (NASDAQ: ARCT) based on AI models. It highlights a strong near- and mid-term sentiment but a weak long-term outlook, identifying exceptional risk-reward setups. The piece outlines specific trading strategies (Position Trading, Momentum Breakout, Risk Hedging) with entry zones, targets, and stop losses, along with a multi-timeframe signal analysis.
2026-01-15 02:59:59
Arcturus Therapeutics presented at the J.P. Morgan Healthcare Conference, showcasing its RNA medicines platform and pipeline. While the conference appearance boosts visibility, the company faces ongoing challenges including financial losses, share price volatility, clinical data progress, funding clarity, and concerns from delayed SEC filings and a recent CFO departure. Investor opinions on ARCT vary widely, with fair value estimates between US$9 and US$72, highlighting the divided sentiment and the importance of execution.
2026-01-15 00:57:48
FEDERATED HERMES, INC. reduced its stake in Arcturus Therapeutics Holdings Inc by 29.62%, selling 1,390,420 shares at $6.13 each. While Arcturus appears undervalued with a GF Value of $11.28, its low profitability, financial distress indicated by an Altman Z score of 0.28, and a Piotroski F-Score of 2 warrant a cautious outlook for investors. This strategic move by Federated Hermes suggests a reevaluation of the biotechnology company's future prospects despite a significant post-transaction gain in ARCT's stock price.
2026-01-14 01:58:04
Arcturus Therapeutics, a clinical-stage biotechnology company, outlined its near-term clinical and regulatory milestones for its mRNA therapy programs at the J.P. Morgan Conference. The company is advancing an inhaled mRNA therapy (ARCT-810) for cystic fibrosis (CF), planning a Phase 2 study with significant funding from the CF Foundation, and another ARCT-810 program for OTC deficiency, which has moved into Phase 2 in both Europe and the U.S., showing promising biomarker signals. With a leaner operating profile and extended cash runway into 2028, Arcturus aims to achieve key clinical and regulatory alignments in 2026.
2026-01-13 03:28:43
Arcturus Therapeutics Holdings Inc. (ARCT) is making progress with its mRNA therapies for cystic fibrosis (CF) and OTC deficiency, supported by strong interim clinical data. The company is targeting significant regulatory milestones for 2026 and maintains financial stability to fund its key studies and platform innovation. This information is based on their recent participation in the 44th Annual J.P. Morgan Healthcare Conference.
2026-01-09 14:28:43
Arcturus Therapeutics Holdings Inc. announced that its President & CEO, Joseph Payne, will present at the 44th Annual J.P. Morgan Healthcare Conference on January 12, 2026. The company is a commercial messenger RNA medicines company focusing on rare disease therapeutics and infectious disease vaccines. Arcturus is known for developing KOSTAIVE®, the first self-amplifying mRNA COVID vaccine, and boasts a broad pipeline and extensive patent portfolio for its RNA therapeutic platforms.
